Complete enrollment in GRATITUDE II Phase 2 trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Nov 2021
- Due
- 31 Dec 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Completion of enrollment in GRATITUDE II, a 150-patient, double-blind, placebo-controlled Phase 2 trial of miricorilant to reverse long-standing AIWG, expected by year-end”
What we found
Evidence strength A What the grades mean
The company confirmed in a February 2022 filing that enrollment for the GRATITUDE II trial had been completed, satisfying the commitment to finish by year-end 2021.
-
A Corcept Therapeutics Inc. 8-K filed 2022-02-15
“Enrollment completed in GRATITUDE II, a 150-patient, double-blind, placebo-controlled Phase 2 trial of miricorilant to reverse long-standing antipsychotic-induced weight gain (AIWG)” ✓ confirmed on the page
-
A Corcept Therapeutics Inc. 8-K filed 2022-02-15
“We are pleased to have fully-enrolled GRATITUDE II” ✓ confirmed on the page
Market reaction: the shares moved +15.1% against the S&P 500 over the three sessions around the disclosure (14 Feb 2022 to 17 Feb 2022). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 3 Nov 2021
Deadline 31 Dec 2021 (“by year-end”) · target 150 patients · wording expected
-
Version 2 · stated 15 Feb 2022
Deadline 30 Jun 2022 (“mid-2022”) · wording expected
“Completion of enrollment in GRATITUDE, a double-blind, placebo-controlled Phase 2 trial of miricorilant to reverse recent AIWG, expected by mid-2022”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- GRATITUDE II trial enrollment
- Target
- 150 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CORT-002840 · Corrections policy